GPR171 Antibody

What is GPR171 and why is it important in research?

GPR171 is an orphan G-protein coupled receptor (GPCR) activated by BigLEN, one of the most abundant neuropeptides in the brain derived from ProSAAS. The receptor contains seven transmembrane domains, an extracellular N-terminus, and an intracellular C-terminal tail. Its structure has been predicted through homology modeling based on similarities to the P2Y12 receptor . The BigLEN-GPR171 neuropeptide-receptor system is primarily expressed in the brain, specifically in the basolateral amygdala (BLA) and periaqueductal gray areas, where it plays crucial roles in regulating feeding behaviors, food intake, body weight regulation, anxiety behaviors, and pain modulation . Recently, GPR171 has also been identified as a potential therapeutic target for obesity, psychiatric disorders, pain management, and certain cancers, making antibodies against this receptor valuable research tools .

What detection methods can be used with GPR171 antibodies?

GPR171 antibodies can be employed in multiple detection methods, each with specific applications in research:

• Western blot analysis: Anti-GPR171 antibodies can detect the receptor in tissue lysates, including rat and mouse brain membranes as well as human cell lines such as MEG-01 megakaryoblastic leukemia cells and Jurkat T-cell leukemia cells .

• Flow cytometry: Both direct and indirect flow cytometry can be performed using anti-GPR171 antibodies. For direct flow cytometry, PE-conjugated anti-GPR171 antibodies can detect the receptor on live intact human Jurkat T-cell leukemia cells and mouse TK-1 T-cell lymphoma cells .

• Live cell imaging: Anti-GPR171 antibodies targeting extracellular epitopes are particularly useful for visualizing the receptor in live cells without the need for permeabilization .

• Immunohistochemistry: These antibodies can be used to detect GPR171 expression in tissue sections, particularly in clinical samples such as lung cancer tissues .

How can researchers validate the specificity of GPR171 antibodies?

Validating antibody specificity is critical for ensuring reliable experimental results. For GPR171 antibodies, the following validation approaches are recommended:

• Blocking peptide experiments: Using a GPR171 extracellular blocking peptide alongside the primary antibody to confirm signal specificity .

• Negative and positive controls: Testing the antibody in cell lines known to be negative for GPR171 expression, then comparing with the same cells after ectopic expression of GPR171. This approach was used to validate specificity in flow cytometry analysis using GPR171-negative MDA-MB-231 cells with or without ectopic expression of GPR171 .

• Multiple detection methods: Confirming GPR171 expression using different methods (western blot, flow cytometry, immunohistochemistry) to cross-validate findings .

• Knockdown verification: Using siRNA or shRNA targeting GPR171 to reduce expression levels and confirm corresponding reduction in antibody signal .

How can GPR171 antibodies be utilized in cancer research?

Recent studies have revealed that GPR171 plays significant roles in cancer biology, particularly in lung cancer:

• Expression analysis: Immunohistochemical analysis using anti-GPR171 antibodies has shown that GPR171 is overexpressed in 46.8% of lung carcinoma tissues but rarely detected in normal bronchial epithelium. Among non-small cell lung cancer (NSCLC) specimens, 45.7% stained positively for GPR171, with variations among subtypes - squamous cell carcinoma, bronchioloalveolar carcinoma, adenosquamous carcinoma, and large-cell carcinoma showing relatively high expression frequencies .

• Therapeutic targeting: Anti-GPR171 antibodies can be used therapeutically in experimental models. Treatment with anti-GPR171 antibody reduced Calu-6 lung cancer cell viability to 28.2% compared to control IgG treatment after 4 days. Furthermore, in a Calu-6 xenograft model, intravenous injection of anti-GPR171 antibody twice weekly for 4 weeks significantly inhibited tumor growth .

• Investigation of metastatic potential: GPR171 is highly expressed at the invading front of squamous cell carcinoma and in cells metastatic to lymph nodes. Studies using GPR171 knockdown showed reduction in both invasion (46.1% and 35.7% reduction) and migration (87% and 44.7% reduction) in lung cancer cell lines .

• Combination therapy research: GPR171 antibodies can be used to investigate synergistic effects with other therapeutic agents. Combined treatment with anti-GPR171 antibody and the EGFR inhibitor AG1478 led to a 66.3% reduction in cell viability, demonstrating a synergistic effect that suggests GPR171 induces tumorigenesis through EGFR-independent mechanisms .

What are the critical methodological considerations when using GPR171 antibodies for flow cytometry?

When employing GPR171 antibodies for flow cytometry, researchers should consider the following methodological aspects:

• Direct vs. indirect detection: For direct detection, PE-conjugated anti-GPR171 antibodies (e.g., #AGR-054-PE) can be used at 2.5-5μg per sample depending on the cell type. For indirect detection, unconjugated primary anti-GPR171 antibodies can be used followed by fluorophore-conjugated secondary antibodies (e.g., goat-anti-rabbit-FITC) .

• Appropriate controls: Include isotype controls such as Rabbit IgG isotype control-PE for direct flow cytometry. For indirect flow cytometry, include cells only and cells with secondary antibody only controls .

• Live cell considerations: Since GPR171 antibodies targeting extracellular epitopes allow for cell surface detection in live intact cells, researchers should optimize cell preparation to maintain viability and surface antigen integrity. Avoid fixation and permeabilization reagents that might alter extracellular epitopes .

• Antibody concentration optimization: Titration experiments should be performed to determine optimal antibody concentrations for specific cell types. For example, human Jurkat T-cell leukemia cells required 2.5μg of anti-GPR171-PE antibody, while mouse TK-1 T-cell lymphoma cells required 5μg for optimal detection .

How can researchers correlate GPR171 expression with functional outcomes in experimental models?

To establish meaningful connections between GPR171 expression and functional effects, consider these approaches:

• Genetic modulation experiments: Use siRNA, shRNA, or CRISPR techniques to knockdown or knockout GPR171 expression. In previous studies, A549 cells expressing GPR171 siRNA #1 or #2 grew approximately 30% and 65% less than cells expressing control siRNA after 3 days. Similar approaches in Calu-6 cells confirmed these effects .

• Overexpression studies: Ectopic expression of GPR171 in normal cells such as WI-38 and IMR-90 normal lung fibroblast cell lines enhanced cell proliferation by 47.1% and 35.2%, respectively, compared to control cells .

• Antibody-based intervention: Use anti-GPR171 antibodies as functional blockers to assess receptor contribution to cellular processes. Treatment with anti-GPR171 antibody has been shown to reduce cell viability and attenuate tumor progression in xenograft models .

• Combined inhibition approaches: Test GPR171 targeting in combination with inhibitors of other pathways to identify potential synergistic effects, such as the demonstrated synergy between GPR171 inhibition and EGFR inhibition in lung cancer models .

How should researchers interpret subcellular localization of GPR171 in immunohistochemistry studies?

Interpreting GPR171 subcellular localization requires careful analysis and consideration of technical factors:

• Expected localization patterns: Immunohistochemistry has shown that GPR171 is expressed in the cytoplasmic membrane and cytoplasm of non-small cell lung cancer cells. The expression levels appear to correlate with differentiation status, being higher in well-differentiated than in poorly-differentiated squamous cell carcinoma .

• Scoring systems: When quantifying GPR171 expression by immunohistochemistry, established scoring systems should be employed. Previous studies have classified expression as "strong" (≥50% positive cells), "moderate" (10-50% positive cells), or "negative" (<10% positive cells) .

• Technical considerations: Antigen retrieval methods significantly impact detection - heating slides in citrate buffer (0.01 M, pH 6.0) using a microwave in a pressure cooker for 15 minutes, followed by cooling for 2 hours at room temperature, has proven effective for GPR171 detection in formalin-fixed tissues .

• Spatial distribution analysis: Pay special attention to expression patterns at tumor margins and invading fronts, as GPR171 has been shown to be highly expressed in these regions, potentially indicating roles in invasion and metastasis .

What are the potential pitfalls in interpreting GPR171 expression data between different experimental systems?

Researchers should be aware of several challenges when comparing GPR171 expression across different systems:

• Discrepancies between mRNA and protein expression: Microarray data do not always reflect protein expression patterns in tissues, necessitating protein-level validation of transcriptomic findings .

• Species differences: While GPR171 is conserved across human, mouse, and rat species, there may be differences in expression patterns, localization, or function. The peptide sequence used for generating anti-GPR171 extracellular antibody corresponds to amino acid residues 155-169 of mouse GPR171 (Accession Q8BG55), which targets the second extracellular loop .

• Context-dependent expression: GPR171 expression and function may vary significantly between normal physiological conditions and pathological states such as cancer. In lung cancer studies, GPR171 was rarely detected in normal bronchial epithelium but overexpressed in 46.8% of lung carcinoma tissues .

• Technical variations: Different detection methods (western blot, flow cytometry, immunohistochemistry) may yield varied results due to differences in sample preparation, antibody accessibility to epitopes, and detection sensitivity.

How can researchers effectively study the interaction between GPR171 and its ligand BigLEN?

To investigate the GPR171-BigLEN interaction, consider these methodological approaches:

• Binding studies: Use fluorescently labeled BigLEN peptide in conjunction with anti-GPR171 antibodies to study binding kinetics, competition with potential inhibitors, and receptor occupancy.

• Functional signaling assays: Measure GPR171 activation upon BigLEN binding through downstream signaling events, such as calcium flux, cAMP production, or ERK phosphorylation. Changes in these parameters following antibody-mediated receptor blockade can confirm specificity.

• Co-localization experiments: Utilize anti-GPR171 antibodies in combination with BigLEN detection to examine their co-localization in tissues of interest, particularly in the basolateral amygdala and periaqueductal gray areas where the BigLEN-GPR171 system is known to be expressed .

• Specificity controls: Include appropriate controls such as GPR171 knockdown/knockout systems or competition with excess unlabeled BigLEN to confirm the specificity of observed interactions.

How might GPR171 antibodies contribute to understanding the role of this receptor in neuropsychiatric disorders?

The BigLEN-GPR171 system's involvement in anxiety behaviors and psychiatric disorders opens several research avenues:

• Expression mapping: Anti-GPR171 antibodies can be used to map receptor expression in brain regions associated with neuropsychiatric disorders, with particular focus on the basolateral amygdala and periaqueductal gray areas .

• Animal behavior models: Administration of GPR171 antibodies in animal models of anxiety, depression, or other psychiatric conditions can help elucidate the receptor's role in these disorders.

• Post-mortem tissue analysis: Examination of GPR171 expression in post-mortem brain tissues from patients with psychiatric disorders compared to healthy controls may reveal disease-specific alterations.

• Drug development: Anti-GPR171 antibodies can serve as tools for screening and validating potential therapeutic compounds targeting this receptor for psychiatric applications .

What methodologies can researchers employ to investigate the therapeutic potential of targeting GPR171 in pain management?

Given the expression of BigLEN-GPR171 in GABAergic neurons within the periaqueductal gray, a key brain area involved in pain modulation and opioid functions, several approaches can be considered:

• Conditional knockdown experiments: Use region-specific GPR171 knockdown in combination with pain behavior assessments to determine the receptor's contribution to pain perception and modulation.

• Antibody-mediated receptor blockade: Administer anti-GPR171 antibodies intrathecally or through other appropriate routes in animal pain models to assess effects on pain thresholds and behaviors.

• Interaction with opioid systems: Investigate potential crosstalk between GPR171 and opioid receptors using co-immunoprecipitation with anti-GPR171 antibodies, followed by detection of opioid receptors or signaling components.

• Neuronal activity measurements: Use anti-GPR171 antibodies in conjunction with electrophysiological recordings or calcium imaging to examine how receptor modulation affects neuronal activity in pain-processing circuits.

How can GPR171 antibodies be utilized in investigating the receptor's role in metabolic regulation?

Previous research has linked GPR171 to feeding behaviors and metabolism, suggesting potential applications in obesity research:

• Hypothalamic expression mapping: Employ anti-GPR171 antibodies to characterize receptor expression in hypothalamic nuclei involved in energy homeostasis and feeding regulation.

• Diet-induced obesity models: Examine changes in GPR171 expression using antibody-based detection methods in animals on different diets or in various metabolic states.

• Peripheral tissue analysis: While GPR171 is known for its brain expression, investigating its presence in peripheral metabolic tissues using specific antibodies may reveal broader metabolic roles.

• Intervention studies: Test the effects of GPR171 blockade using antibodies on food intake, body weight, and metabolic parameters in animal models to assess therapeutic potential for obesity .

What statistical approaches are most appropriate for analyzing GPR171 expression data in clinical samples?

When analyzing GPR171 expression in clinical samples, researchers should consider these statistical approaches:

• Categorical analysis: For immunohistochemistry data scored as "strong," "moderate," or "negative," use chi-square or Fisher's exact tests to compare expression frequencies between different groups (e.g., cancer vs. normal, different cancer subtypes) .

• Correlation analysis: Employ Spearman's or Pearson's correlation to examine relationships between GPR171 expression levels and clinical parameters, disease stage, or patient outcomes.

• Survival analysis: Kaplan-Meier curves with log-rank tests can be used to assess relationships between GPR171 expression and patient survival or disease progression.

• Multivariate analysis: Cox proportional hazards models or multiple regression can help determine whether GPR171 expression is an independent predictor of outcomes when controlling for other clinical variables.

• Sample size considerations: Previous studies examined 47 lung cancer tissues, of which 22 (46.8%) were positive for GPR171. Similar sample sizes should be considered for adequate statistical power .

How should researchers address potential inconsistencies between GPR171 antibody-based detection methods?

When faced with divergent results from different detection methods, consider these approaches:

• Method validation hierarchy: Establish a hierarchy of methods based on specificity and sensitivity. For GPR171, immunoblotting with appropriate controls may provide more quantitative results than immunohistochemistry.

• Epitope accessibility: Different antibodies may target distinct epitopes with varying accessibility depending on the method. Anti-GPR171 (extracellular) antibodies target the second extracellular loop (amino acids 155-169 in mouse), which may be differentially accessible in various applications .

• Confirmatory approaches: Use multiple antibodies targeting different epitopes of GPR171 to confirm expression patterns. Additionally, complement antibody-based methods with mRNA detection or functional assays.

• Protocol optimization: Systematic optimization of protocols for each method (fixing conditions, antigen retrieval, blocking, antibody concentration) may resolve apparent inconsistencies.